Finance

Lists
Q3 2026 earnings • released • EPS miss -254.80% • Revenue beat +4.76%
See results
CTEV:NYSE
Claritev Corp
$28.21
-1.60%
(-0.46) 1D
$28.21
0.00% (0.00)
After hours
Closed: Nov 11, 4:00:04 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CTEV...
Open
$28.67
High
$30.20
Low
$26.83
Mkt. cap
478.09M
Avg. vol.
261.16K
Volume
437.98K
52-wk high
$61.22
52-wk low
$11.50
EPS
-$17.00
Beta
1.05
Shares outstanding
17.08M
No. of employees
3K
Open
$28.67
High
$30.20
Low
$26.83
Mkt. cap
478.09M
Avg. vol.
261.16K
Volume
437.98K
52-wk high
$61.22
52-wk low
$11.50
EPS
-$17.00
Beta
1.05
Shares outstanding
17.08M
No. of employees
3K
News stories
From web sources and news partners
About Claritev Corp
CEO-
Employees3K
Founded1980
Headquarters-
SectorHealth Care
Industry-
Websiteclaritev.com
Analyst ratings
Based on 5 analysts giving stock ratings to CTEV in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for CTEV in the last 3 months.
Highest
Current $28.21
$73.00 (+158.77%)
Average
$46.80 (+65.90%)
Lowest
$30.00 (+6.35%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Guggenheim
Buy
Maintained
$44.00
+56%
11/09/2026
Richard Close
Canaccord Genuity
Buy
Maintained
$47.00
+66.6%
11/10/2026
Stan Berenshteyn
Wells Fargo
Hold
Maintained
$30.00
+6.3%
11/10/2026
Glen Santangelo
Barclays
Buy
Maintained
$40.00
+41.8%
10/13/2026
Jessica Tassan
Piper Sandler
Buy
Reiterated
$73.00
+158.8%
08/18/2026
Daniel Grosslight
Citi
Buy
Maintained
$45.00
+59.5%
08/10/2026
Jason Cassorla
Guggenheim
Buy
Reiterated
$44.00
+56%
08/07/2026
Last report
Nov 9, 2026
Fiscal period
Q3 2026
-$2.65 / $1.71
-254.80%miss
Revenue / Est. (USD)
268.31M / 256.13M
+4.76%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
245.96M
246.55M
244.68M
257.48M
Cost of goods sold
62.06M
70.09M
69.08M
67.67M
Cost of revenue
62.06M
70.09M
69.08M
67.67M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
48.01M
40.64M
46.04M
46.14M
Operating expense
159.95M
152.37M
157.13M
156.84M
Total operating expenses
222.01M
222.46M
226.21M
224.51M
Operating income
23.95M
24.09M
18.47M
32.97M
Other non operating income
-
-
-
-
EBT including unusual items
-93.36M
-106.92M
-92.72M
-76.65M
EBT excluding unusual items
-76.81M
-75.04M
-80.89M
-67.09M
Income tax expense
-23.61M
-26.35M
-19.16M
-17.42M
Effective tax rate
25.29%
24.64%
20.67%
22.73%
Other operating expenses
-
-
-
-
Net income
-69.75M
-80.57M
-73.56M
-59.23M
Net profit margin
-28.36%
-32.68%
-30.06%
-23.00%
Earnings per share
-
-3.19
-3.30
-2.94
Interest and investment income
471.00K
279.00K
182.00K
195.00K
Interest expense
-101.23M
-99.41M
-99.54M
-100.25M
Net interest expenses
-100.76M
-99.13M
-99.36M
-100.06M
Depreciation and amortization charges
25.97M
25.89M
25.18M
24.80M
EBITDA
135.89M
135.83M
129.56M
143.67M
Gain or loss from assets sale
196.00K
8.68M
-
57.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps